TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Regeneus Ltd. ( (AU:CMB) ) has issued an announcement.
Cambium Bio Limited has signed a Memorandum of Understanding with Benta SAS to commercialize Elate Ocular® for dry eye disease in Europe and the Middle East. This partnership marks Cambium’s second platelet-lysate licensing deal in three days, highlighting strong commercial interest in its platform technology. The collaboration with Benta, a leading pharmaceutical company with extensive manufacturing and distribution capabilities, is expected to enhance Cambium’s market presence and leverage Benta’s expertise in blood-derived therapeutics and ophthalmology.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing and commercializing innovative therapies using platelet-lysate technology.
Average Trading Volume: 17,891
Technical Sentiment Signal: Sell
Current Market Cap: A$10.74M
See more insights into CMB stock on TipRanks’ Stock Analysis page.